Recurrent Fallopian Tube Carcinoma
Showing 26 - 50 of 54
Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston
Recruiting
- Malignant Female Reproductive System Neoplasm
- +24 more
- Quality-of-Life Assessment
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 6, 2022
Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Aurora
Active, not recruiting
- Recurrent Endometrial Serous Adenocarcinoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
May 24, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +6 more
- Lenvatinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 17, 2022
Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in
Recruiting
- Malignant Ovarian Epithelial Tumor
- +9 more
- Akt/ERK Inhibitor ONC201
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
May 10, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Seattle
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Carboplatin
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 10, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Buffalo
Active, not recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Aldesleukin
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Mar 3, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +44 more
Jan 10, 2022
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Los Angeles
Recruiting
- Recurrent Endometrial Carcinoma
- +3 more
- Abemaciclib
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 28, 2021
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Bronx, New York
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Carboplatin
- +2 more
-
Bronx, New York
- +2 more
Oct 18, 2021
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Completed
- Fallopian Tube Clear Cell Adenocarcinoma
- +17 more
- Elesclomol Sodium
- Paclitaxel
-
Phoenix, Arizona
- +162 more
Sep 28, 2021
Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma Trial in Jacksonville,
Completed
- Ovarian Endometrioid Adenocarcinoma
- +8 more
- Everolimus
- +2 more
-
Jacksonville, Florida
- +1 more
Sep 28, 2020
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous
Withdrawn
- High Grade Fallopian Tube Serous Adenocarcinoma
- +5 more
- Birinapant
- +3 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jul 22, 2020
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Completed
- Fallopian Tube Clear Cell Adenocarcinoma
- +19 more
- Bortezomib
- +3 more
-
Hartford, Connecticut
- +13 more
Aug 8, 2019
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- +3 more
-
Mobile, Alabama
- +141 more
Jul 22, 2019
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma Trial in United
Completed
- Ovarian Clear Cell Cystadenocarcinoma
- +7 more
- Bevacizumab
- +4 more
-
Aurora, Colorado
- +12 more
Jul 19, 2019
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma Trial in United
Completed
- Ovarian Clear Cell Cystadenocarcinoma
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +6 more
Mar 8, 2019
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma Trial in Canada,
Completed
- Adult Hepatocellular Carcinoma
- +44 more
- Bevacizumab
- Temsirolimus
-
Scottsdale, Arizona
- +60 more
Jan 24, 2019
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier Trial in United States (Laboratory Biomarker
Completed
- Basal-Like Breast Carcinoma
- +16 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +6 more
Jun 28, 2018
Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Duarte
Completed
- Recurrent Ovarian Epithelial Cancer
- +2 more
- modified vaccinia virus ankara vaccine expressing p53
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 26, 2018
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma Trial in Bronx, New York (Laboratory Biomarker Analysis,
Completed
- Estrogen Receptor Negative
- +9 more
- Laboratory Biomarker Analysis
- +3 more
-
Bronx, New York
- +5 more
Dec 21, 2017
Adult Solid Tumor, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma Trial in Baltimore, Toronto (other, radiation,
Completed
- Adult Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +3 more
-
Baltimore, Maryland
- +2 more
Nov 20, 2017
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- Rilotumumab
-
Burbank, California
- +27 more
Aug 8, 2017
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Canada, United
Completed
- Recurrent Fallopian Tube Carcinoma
- +5 more
- Gamma-Secretase Inhibitor RO4929097
- Laboratory Biomarker Analysis
-
Beverly Hills, California
- +11 more
Apr 17, 2017
Collecting Tumor Samples From Patients With Gynecological Tumors
Completed
- Borderline Ovarian Clear Cell Tumor
- +85 more
- Laboratory Biomarker Analysis
-
Fayetteville, Arkansas
- +186 more
Oct 26, 2016
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Columbus
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- Wild-type Reovirus
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 5, 2016